IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Monday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Up 2.4 %

NASDAQ IRIX opened at $1.69 on Monday. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65. The stock has a market cap of $28.12 million, a P/E ratio of -2.52 and a beta of 0.82. The stock’s fifty day moving average price is $1.73 and its 200-day moving average price is $1.79. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The company had revenue of $11.58 million during the quarter. During the same quarter in the prior year, the company posted ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.